Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take it. Plus, Novartis implemented a novel pricing policy: if the therapy doesn’t work within 30 days, Novartis doesn’t get paid.